Psoriatic arthritis (PsA) is a chronic, progressive disease that, untreated, may be associated with permanent joint damage, disability, impaired quality of life, and cardiovascular disease. Globally, it affects 0.1-1% of people, it is a common comorbidity of patients with psoriasis, affecting up to a quarter of those with moderate-to-severe disease. affecting them in a quarter percent of the U.S. population. PsA is an immune-mediated disease characterized by inflammation of the skin and nails disease or a family history of psoriasis in association with pluralistic musculoskeletal disease that may involve entheses, the spine, and peripheral joints. Unlike the clinical manifestations of inflammatory, pathophysiological processes of psoriasis, a failure to intervene early in PsA with treatment often results in damage that is irreversible. In all, patients with PsA incur about four times the direct medical costs as compared to the average medical patient.
This accredited educational activity identifies the critical components of the management process and offer solutions to close gaps in diagnosis and care, with the ultimate goals being the improvement of psoriatic arthritis management, treatment adherence, and health and cost outcomes.
The following HCPs: rheumatologists, dermatologists, and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in rheumatology and immunology; and any other HCPs with an interest in or who clinically encounter patients with PsA.
This program is supported by an educational grant from Mylan Inc., a Viatris Company.
This activity is free of charge.
Release Date: May 15, 2022 -- Expiration Date: May 15, 2024
Faculty: Peng Fan, MD
Introduction content: cursory refresher and review of PsA
Epidemiology: statistics by severity
Clinical presentation; disease progression; complications, comorbidities, and burden of disease
Evaluation, diagnosis, and associated pitfalls
Treatment of PsA
Peripheral arthritis vs. axial disease
Moderate-to-severe disease treatment
cDMARDs: methotrexate, leflunomide, and phosphodiesterase-4 inhibition
Adverse prognosis and resistance to cDMARDs
Tumor necrosis factor-targeting therapy
IL-17, -12, and -23-targeting therapies
Selective T-cell costimulation
Janus kinase inhibition
Recent clinical trial evidence and guideline updates
Emerging and future therapies
Disease flares and adverse events
Summary, conclusions, and best practice recap
By the end of the session the participant will be able to:
This activity is not accredited.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, CEO of ScientiaCME, has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by an educational grant from Mylan Inc., a Viatris Company.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.